JNJ
JOHNSON & JOHNSON
Key Financials
Revenue
$94.2B
↑ 6.0%
Operating Income
$21.6B
↑ 31.6%
Gross Profit
$63.9B
↑ 4.2%
Total Assets
$199.2B
↑ 10.6%
EPS (Diluted)
$11.03
↑ 90.5%
Net Income
$26.8B
↑ 90.6%
Total Liabilities
$117.7B
↑ 8.3%
Cash & Equivalents
$19.7B
↓ 18.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/14/2026 | View on SEC |
| SCHEDULE 13G/A | 4/13/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 13F-HR/A | 3/18/2026 | View on SEC |
| 13F-HR/A | 3/18/2026 | View on SEC |
| 4 | 3/12/2026 | View on SEC |
| 4 | 3/12/2026 | View on SEC |
| 4 | 3/12/2026 | View on SEC |
| ARS | 3/11/2026 | View on SEC |
| DEFA14A | 3/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | JNJ |
| Company Name | JOHNSON & JOHNSON |
| CIK | 200406 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1228 |
| State of Incorporation | NJ |
| Phone | 732-524-2455 |